Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score–matched cohort study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score–matched cohort study

Published:2021-02 Issue:2 Volume:84 Page:300-311
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Schneeweiss Maria C.,Kim Seoyoung C.,Wyss Richard,Schneeweiss Sebastian,Merola Joseph F.

Funder

Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital

Pfizer

AbbVie

Roche

Bristol Myers Squibb

US Food and Drug Adminstration

National Institutes of Health

Patient-Centered Outcomes Research Institute

Bayer

Vertex

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Dermatology

Reference33 articles.

1. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis;Beck;N Engl J Med,2014

2. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD);Simpson;J Am Acad Dermatol,2016

3. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial;Thaci;Lancet,2016

4. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis;Simpson;N Engl J Med,2016

5. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial;Blauvelt;Lancet,2017

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review;Dermatology and Therapy;2024-07-16

2. Reappraising the Use of Systemic Immunomodulators for Psoriasis and Eczema in the Military;Military Medicine;2024-04-11

3. Concepts of Designing and Implementing Pharmacoepidemiology Studies on the Safety of Systemic Treatments in Dermatology Practice;JID Innovations;2023-11

4. Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study;Journal of the American Academy of Dermatology;2023-10

5. Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials;JAMA Network Open;2023-09-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3